Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock Rating Reaffirmed by JMP Securities

Deciphera Pharmaceuticals (NASDAQ:DCPH)‘s stock had its “market perform” rating reaffirmed by JMP Securities in a research note issued on Tuesday, Benzinga reports.

Several other analysts have also weighed in on the company. JPMorgan Chase & Co. raised their price objective on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Wednesday, March 20th. Jefferies Financial Group reissued a “hold” rating and set a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research note on Monday. Jonestrading reissued a “hold” rating and set a $25.60 price target on shares of Deciphera Pharmaceuticals in a research note on Monday. Barclays raised Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $9.00 to $26.00 in a research note on Tuesday. Finally, Stifel Nicolaus lifted their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $24.17.

Deciphera Pharmaceuticals Trading Up 0.2 %

DCPH stock traded up $0.05 during trading hours on Tuesday, hitting $25.33. 2,096,393 shares of the stock were exchanged, compared to its average volume of 1,143,882. The firm has a market capitalization of $2.08 billion, a P/E ratio of -11.06 and a beta of 0.39. The company has a 50-day simple moving average of $15.78 and a two-hundred day simple moving average of $14.45. Deciphera Pharmaceuticals has a 12 month low of $9.90 and a 12 month high of $25.40.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. The company had revenue of $48.30 million for the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. Deciphera Pharmaceuticals’s quarterly revenue was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.60) EPS. On average, equities research analysts predict that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of hedge funds have recently made changes to their positions in DCPH. China Universal Asset Management Co. Ltd. increased its holdings in Deciphera Pharmaceuticals by 67.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 15,513 shares of the company’s stock worth $244,000 after purchasing an additional 6,241 shares in the last quarter. Diversified Trust Co grew its stake in Deciphera Pharmaceuticals by 6.5% in the first quarter. Diversified Trust Co now owns 12,747 shares of the company’s stock valued at $201,000 after acquiring an additional 778 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Deciphera Pharmaceuticals in the first quarter valued at approximately $291,000. Fisher Asset Management LLC acquired a new stake in Deciphera Pharmaceuticals in the fourth quarter valued at approximately $1,006,000. Finally, Goldman Sachs Group Inc. grew its stake in Deciphera Pharmaceuticals by 14.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,307,475 shares of the company’s stock valued at $37,220,000 after acquiring an additional 290,968 shares during the period. 70.96% of the stock is currently owned by institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.